OBJECTIVE: Neuregulin 1 (NRG1) is a multifunctional neurotrophin that mediates neurodevelopment and schizophrenia risk. The NRG1 gene undergoes extensive alternative splicing, and association of brain NRG1 type IV isoform expression with the schizophrenia-risk polymorphism rs6994992 is a potential mechanism of risk. Novel splice variants of NRG1-IV (NRG1-IVNV), with predicted unique signaling capabilities, have been cloned in fetal brain tissue. The authors investigated the temporal dynamics of transcription of NRG1-IVNV, compared with the major NRG1 isoforms, across human prenatal and postnatal prefrontal cortical development, and they examined the association of rs6994992 with NRG1-IVNV expression. METHOD: NRG1 type I-IV and NRG1-IVNV isoforms were evaluated with quantitative real-time polymerase chain reaction in human postmortem prefrontal cortex tissue samples at 14 to 39 weeks gestation and postnatal ages 0-83 years. The association of rs6994992 genotype with NRG1-IVNV expression and the subcellular distribution and proteolytic processing of NRG1-IVNV isoforms were also determined. RESULTS: Expression of NRG1 types I, II, and III was temporally regulated during prenatal and postnatal neocortical development. NRG1-IVNV was expressed from 16 weeks gestation until age 3. Homozygosity for the schizophrenia risk allele (T) of rs6994992 conferred lower cortical NRG1-IVNV levels. Assays showed that NRG1-IVNV is a novel nuclear-enriched, truncated NRG1 protein resistant to proteolytic processing. CONCLUSIONS: To the authors' knowledge, this study provides the first quantitative map of NRG1 isoform expression during human neocortical development and aging. It identifies a potential mechanism of early developmental risk for schizophrenia at the NRG1 locus, involving a novel class of NRG1 proteins.
OBJECTIVE:Neuregulin 1 (NRG1) is a multifunctional neurotrophin that mediates neurodevelopment and schizophrenia risk. The NRG1 gene undergoes extensive alternative splicing, and association of brain NRG1 type IV isoform expression with the schizophrenia-risk polymorphism rs6994992 is a potential mechanism of risk. Novel splice variants of NRG1-IV (NRG1-IVNV), with predicted unique signaling capabilities, have been cloned in fetal brain tissue. The authors investigated the temporal dynamics of transcription of NRG1-IVNV, compared with the major NRG1 isoforms, across human prenatal and postnatal prefrontal cortical development, and they examined the association of rs6994992 with NRG1-IVNV expression. METHOD:NRG1 type I-IV and NRG1-IVNV isoforms were evaluated with quantitative real-time polymerase chain reaction in human postmortem prefrontal cortex tissue samples at 14 to 39 weeks gestation and postnatal ages 0-83 years. The association of rs6994992 genotype with NRG1-IVNV expression and the subcellular distribution and proteolytic processing of NRG1-IVNV isoforms were also determined. RESULTS: Expression of NRG1 types I, II, and III was temporally regulated during prenatal and postnatal neocortical development. NRG1-IVNV was expressed from 16 weeks gestation until age 3. Homozygosity for the schizophrenia risk allele (T) of rs6994992 conferred lower cortical NRG1-IVNV levels. Assays showed that NRG1-IVNV is a novel nuclear-enriched, truncated NRG1 protein resistant to proteolytic processing. CONCLUSIONS: To the authors' knowledge, this study provides the first quantitative map of NRG1 isoform expression during human neocortical development and aging. It identifies a potential mechanism of early developmental risk for schizophrenia at the NRG1 locus, involving a novel class of NRG1 proteins.
Authors: D Wen; S V Suggs; D Karunagaran; N Liu; R L Cupples; Y Luo; A M Janssen; N Ben-Baruch; D B Trollinger; V L Jacobsen Journal: Mol Cell Biol Date: 1994-03 Impact factor: 4.272
Authors: Rosie M Walker; Andrea Christoforou; Pippa A Thomson; Kevin A McGhee; Alan Maclean; Thomas W Mühleisen; Jana Strohmaier; Vanessa Nieratschker; Markus M Nöthen; Marcella Rietschel; Sven Cichon; Stewart W Morris; Omer Jilani; David Stclair; Douglas H Blackwood; Walter J Muir; David J Porteous; Kathryn L Evans Journal: Neurosci Lett Date: 2010-05-07 Impact factor: 3.046
Authors: Carlo Colantuoni; Barbara K Lipska; Tianzhang Ye; Thomas M Hyde; Ran Tao; Jeffrey T Leek; Elizabeth A Colantuoni; Abdel G Elkahloun; Mary M Herman; Daniel R Weinberger; Joel E Kleinman Journal: Nature Date: 2011-10-26 Impact factor: 49.962
Authors: Emily Moon; Brandi Rollins; Andrea Mesén; Adolfo Sequeira; Richard M Myers; Huda Akil; Stanley J Watson; Jack Barchas; Edward G Jones; Alan Schatzberg; William E Bunney; Lynn E DeLisi; William Byerley; Marquis P Vawter Journal: Schizophr Res Date: 2011-07-13 Impact factor: 4.939
Authors: A P Corvin; D W Morris; K McGhee; S Schwaiger; P Scully; J Quinn; D Meagher; D St Clair; J L Waddington; M Gill Journal: Mol Psychiatry Date: 2004-02 Impact factor: 15.992
Authors: Clare Paterson; Yanhong Wang; Thomas M Hyde; Daniel R Weinberger; Joel E Kleinman; Amanda J Law Journal: Am J Psychiatry Date: 2016-10-24 Impact factor: 18.112
Authors: Monica Uddin; Andrew Ratanatharathorn; Don Armstrong; Pei-Fen Kuan; Allison E Aiello; Evelyn J Bromet; Sandro Galea; Karestan C Koenen; Benjamin Luft; Kerry J Ressler; Derek E Wildman; Caroline M Nievergelt; Alicia Smith Journal: Epigenomics Date: 2018-11-20 Impact factor: 4.778
Authors: Aintzane García-Bea; Mary A Walker; Thomas M Hyde; Joel E Kleinman; Paul J Harrison; Tracy A Lane Journal: Schizophr Res Date: 2016-04-27 Impact factor: 4.939
Authors: Juan C Olaya; Carrie L Heusner; Mitsuyuki Matsumoto; Duncan Sinclair; Mari A Kondo; Tim Karl; Cynthia Shannon Weickert Journal: Schizophr Bull Date: 2018-06-06 Impact factor: 9.306